Pembrolizumab Eligibility for TMB-High Solid Tumors

What the traditional approval covers

The FDA’s October 16, 2026, decision applies to adults and pediatric patients with unresectable or metastatic tumor mutational burden-high, or TMB-high, solid tumors. The tumor must have at least 10 mutations per megabase, as determined by an FDA-approved test. It must also have progressed after prior treatment, and the patient must have no satisfactory alternative treatment options.

Those requirements are cumulative. A positive TMB result does not independently establish eligibility, nor does advanced disease without documented progression after prior therapy. Treatment review therefore needs to address biomarker status, disease extent, treatment history, and the remaining disease-specific options.

Traditional approval changes the regulatory status of the tissue-agnostic indication, which initially received accelerated approval in 2020. It does not turn pembrolizumab into a general first-line treatment for every TMB-high cancer or replace tumor-specific indications that may authorize its use in different settings.

“Unresectable” and “metastatic” describe alternative routes into the disease-stage requirement; both are not necessary. By contrast, advanced disease, post-treatment progression and the absence of satisfactory alternatives all remain part of the indication. Whether an alternative is satisfactory requires disease-specific clinical judgment rather than a biomarker-only determination.

Evidence behind the tissue-agnostic indication

The original accelerated approval was supported by a prespecified retrospective biomarker analysis of KEYNOTE-158, a prospective, open-label, multicohort phase 2 study of pembrolizumab in previously treated advanced solid tumors. The pivotal efficacy population included 102 patients whose tumors had TMB of at least 10 mutations per megabase using the specified companion diagnostic.

There was no randomized comparator. The objective response rate in the TMB-high group was 29%, with a 95% confidence interval of 21% to 39%; 4% had a complete response and 25% had a partial response. Among 688 evaluable patients with lower TMB, the response rate was 6% (95% CI, 5% to 8%). Median study follow-up in the published biomarker analysis was 37.1 months.

Duration supported the initial signal: 57% of responding patients in the TMB-high efficacy population had responses lasting at least 12 months, and 50% had responses lasting at least 24 months. These were single-arm response data, not evidence of improved survival over standard treatment. Cross-group differences between TMB-high and non-TMB-high tumors also cannot establish that the biomarker caused the observed treatment effect.

The FDA’s traditional approval notice is the controlling source for the current indication. The historical KEYNOTE-158 results explain why response activity was considered clinically meaningful, but clinicians should not treat those results as a direct comparison with every tumor-specific therapy now available.

Applying all three clinical requirements

First, the tumor must be unresectable or metastatic. “Unresectable” should reflect the multidisciplinary assessment appropriate to the cancer type and disease distribution. A patient does not qualify under this indication merely because surgery would be inconvenient, declined or deferred without a clinical determination that the disease cannot be satisfactorily resected.

Second, the disease must have progressed after prior treatment. The indication is not written as biomarker-selected initial therapy. The relevant prior treatment depends on the tumor and clinical context, and a separate tumor-specific pembrolizumab indication may apply earlier in the treatment course.

Third, no satisfactory alternative treatment options may remain. This is broader than asking whether another drug technically exists. Review may account for expected benefit, contraindications, prior exposure, resistance, toxicity and the applicability of tumor-specific standards. Conversely, do not use the TMB-high indication to bypass an established option solely because pembrolizumab is available.

Pediatric patients are expressly included. However, inclusion in the indication does not mean children were proportionately represented across the tumor cohorts that generated the efficacy estimate. Pediatric review should confirm the current prescribing information, the selected product’s authorized population and presentation, and whether a more specific pediatric tumor indication or established treatment pathway applies.

Pembrolizumab alone versus the fixed combination

The approval lists pembrolizumab and pembrolizumab with berahyaluronidase alfa as product options. These are not instructions to add separately supplied berahyaluronidase alfa to pembrolizumab, and they do not describe a two-drug anticancer regimen in which each component has independent antitumor activity.

Pembrolizumab alone refers to the established single-agent product. Pembrolizumab and berahyaluronidase alfa is a fixed-combination presentation in which the hyaluronidase component facilitates subcutaneous administration. It should not be confused with combining pembrolizumab with chemotherapy, a targeted agent or another immunotherapy.

The formulation listing also does not erase product-specific restrictions. Before selecting a presentation for an adult or child, clinicians need to consult the current prescribing information for the authorized age or weight group, route, dosing framework, contraindications and preparation requirements. The FDA decision should not be interpreted as making the products interchangeable in every patient or care setting.

Important limits on interpretation

KEYNOTE-158 was nonrandomized and included multiple tumor types with unequal representation. The 102-patient TMB-high efficacy population was too small to establish the same magnitude of benefit for every histology, and response rate is not a substitute for comparative overall-survival or quality-of-life evidence.

Assay choice also matters. The indication specifies an FDA-approved test and a threshold of at least 10 mutations per megabase; results from different platforms may not be analytically interchangeable. Tumor biology, prior therapy and other biomarkers can further influence the likelihood of response.

Finally, the tissue-agnostic indication operates alongside a changing set of tumor-specific approvals and standards. A patient may meet its literal biomarker and stage criteria yet still have a satisfactory alternative. That makes the indication a framework for treatment review, not an automatic treatment rule.

Questions clinicians ask

Does any TMB-high solid tumor qualify?

No. The result must meet the threshold of at least 10 mutations per megabase on an FDA-approved test, and the tumor must be unresectable or metastatic. The disease must also have progressed after prior treatment, with no satisfactory alternative treatment option remaining.

Can pembrolizumab be used first line under this indication?

Not on the basis of this tissue-agnostic indication alone, because its wording requires progression after prior treatment. A separate tumor-specific pembrolizumab indication may authorize first-line use, but that is a distinct regulatory pathway with its own biomarker, disease-stage and combination requirements.

Are pediatric patients included on the same basis as adults?

The approval includes adult and pediatric patients under the same core disease, biomarker, progression and alternative-treatment criteria. Clinicians should still verify the current prescribing information for product-specific pediatric eligibility and recognize that the pivotal TMB-high dataset did not provide equally robust evidence across pediatric tumor types.

Is berahyaluronidase alfa an additional cancer treatment?

No. In the listed fixed combination, berahyaluronidase alfa facilitates subcutaneous delivery of pembrolizumab; it is not presented as a separate antitumor partner. The fixed combination should be distinguished from pembrolizumab monotherapy and from regimens that pair pembrolizumab with chemotherapy or another systemic anticancer agent.

References

1. FDA grants traditional approval to pembrolizumab for TMB-high solid tumors — US Food and Drug Administration, 2026 2. Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) — ClinicalTrials.gov, 2015 3. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study — The Lancet Oncology, 2020